Coya Therapeutics Raises $11.1M in Private Placement to Advance ALS Therapy
Event summary
- Coya Therapeutics secured $11.1M in a private placement at $4.40 per share, closing on January 30, 2026.
- Investors include Dr. Reddy’s Laboratories ($10M) and Greenlight Capital ($1.1M).
- Proceeds will accelerate tech transfer and scale-up manufacturing for COYA 302, its lead ALS therapy.
- Company agreed to file a registration statement with the SEC for resale of the securities within 45 days.
The big picture
Coya’s $11.1M private placement underscores the growing investor interest in neurodegenerative disease therapies, particularly those targeting ALS. The funding comes at a critical juncture as the company advances its Phase 2 ALSTARS Trial, positioning it within a competitive landscape of biotechs racing to develop immunomodulatory treatments. The strategic backing from Dr. Reddy’s Laboratories suggests potential downstream collaborations, though the immediate focus remains on scaling manufacturing for COYA 302.
What we're watching
- Execution Risk
- Whether Coya can efficiently deploy the $11.1M to meet commercial readiness timelines for COYA 302.
- Regulatory Dynamics
- The pace at which the SEC registration process for resale of securities will be completed.
- Strategic Alignment
- How the involvement of Dr. Reddy’s Laboratories may influence future partnerships or commercialization strategies.
Related topics